Medtronic plc — Form 10-K summary
Business context and reporting period
Medtronic is a global medical technology company operating in more than 150 countries across Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. Despite the request metadata referring to “2017 Q4,” this filing is the annual report for fiscal 2018, the 52 weeks ended April 27, 2018; fiscal 2017 ended April 28, 2017. Amounts below are U.S. dollars.
Financial performance and position
| Metric | FY2018 | FY2017 |
|---|---|---|
| Net sales | $29.953 billion | $29.710 billion |
| Gross profit / margin | $20.898 billion / 69.8% | $20.419 billion / 68.7% |
| Operating profit / margin | $6.651 billion / 22.2% | $5.330 billion / 17.9% |
| Net income attributable to Medtronic | $3.104 billion | $4.028 billion |
| Diluted EPS | $2.27 | $2.89 |
| Operating cash flow | $4.684 billion | $6.880 billion |
| Free cash flow (non-GAAP) | $3.616 billion | $5.626 billion |
- Sales increased 0.8%; currency contributed a favorable $494 million. Emerging-market sales grew 12%, while U.S. sales fell 5%, partly reflecting the divestiture described below.
- FY2018 reported earnings included a $2.4 billion net tax charge associated with U.S. tax reform, a $227 million investment impairment loss, and a $68 million impairment of in-process research and development. Management’s non-GAAP diluted EPS was $4.77 versus $4.60 in FY2017; these adjusted figures exclude specified items.
- Cash and cash equivalents were $3.669 billion and current investments were $7.558 billion at year-end. Working capital was $12.896 billion and the current ratio was 2.3, compared with 1.7 in FY2017.
- Total debt was approximately $25.8 billion, down from $33.4 billion; current debt was $2.058 billion and long-term debt $23.699 billion. Shareholders’ equity was $50.720 billion.
- Dividends declared were $1.84 per share, up from $1.72. The company repurchased $2.171 billion of shares during FY2018.
Material changes versus the prior year
- FY2018 sales rose modestly, but attributable net income fell 23% and diluted EPS fell 21%, primarily because of the tax-reform charge. Operating profit rose 25%, but included a $697 million pre-tax gain on the divestiture of businesses.
- On July 29, 2017, Medtronic sold its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health for net proceeds of $6.1 billion, recording a $697 million pre-tax gain. FY2018 sales from those businesses were $0.6 billion versus $2.4 billion in FY2017. This materially affects comparisons, particularly for Minimally Invasive Therapies, whose reported sales declined 12%.
- Sales increased 8% in Cardiac and Vascular, 5% in Restorative Therapies, and 11% in Diabetes. Minimally Invasive Therapies sales declined to $8.716 billion, primarily due to the divestiture.
- Operating cash flow fell by $2.2 billion, largely due to higher cash taxes, including a $1.1 billion advance payment to the IRS related to Puerto Rico transfer-pricing litigation, and lower customer collections. Investing cash flow included the divestiture proceeds; financing cash flow reflected substantial debt repayments.
Outlook, commentary, risks, and unusual items
- Management emphasized therapy innovation, expansion in underpenetrated markets, and value-based healthcare. It cited new product launches and 12% emerging-market sales growth as contributors to performance.
- The Enterprise Excellence program, announced in FY2018, targets more than $3.0 billion in annual gross savings by the end of FY2022, with approximately $500–$700 million expected per year through FY2022. Estimated pre-tax restructuring charges are $1.6–$1.8 billion, with most expected by FY2022 and cash outlays substantially complete by FY2023.
- The filing does not provide a clear consolidated FY2019 revenue or EPS forecast. Management’s outlook is principally strategic and segment-specific, and identifies competitive launches, pricing pressure, reimbursement changes, regulatory timing, procedural volumes, product replacement cycles, macroeconomic conditions, and currency movements as factors affecting performance.
- Material exposures include approximately $0.9 billion of accrued litigation at year-end; the ongoing IRS dispute over income allocation between Medtronic and its Puerto Rico subsidiary; and other tax audits and uncertain tax positions. The company made a $1.1 billion IRS advance payment, but the outcome of the Puerto Rico tax matters remains uncertain.
- Regulatory matters include continuing FDA audits and obligations under the SynchroMed consent decree through 2020, as well as FDA Warning Letter matters involving TYRX and HeartWare. The SynchroMed manufacturing and distribution restrictions were lifted in September 2017.
- Operational risks include product quality and liability claims, supply interruptions and sole-source components, pricing and reimbursement pressure, cybersecurity, and facility disruption. The company reported a June 2017 IT interruption and Hurricane Maria-related disruption and costs in Puerto Rico.
- Tax-reform accounting remained provisional at year-end. Medtronic also reported $321 million of gross unrealized losses on available-for-sale debt securities and funds, and noted limited liquidity in auction-rate securities.
Most important facts for investors to verify
- Separate recurring operating performance from the $697 million divestiture gain, $2.4 billion tax-reform charge, investment and IPR&D impairments, and other adjustments; reconcile GAAP results with management’s non-GAAP measures.
- Assess the underlying sales trajectory and comparability after the Cardinal divestiture, including growth across each segment and the transition service and manufacturing agreements.
- Track cash conversion: operating cash flow and free cash flow declined materially; review the sustainability of cash generation alongside dividends and repurchases.
- Evaluate debt maturities and the capacity to fund obligations and restructuring while maintaining shareholder returns; reported debt was approximately $25.8 billion at year-end.
- Monitor the IRS Puerto Rico transfer-pricing appeal and other tax exposures, including any revisions to provisional Tax Act accounting.
- Follow delivery of the Enterprise Excellence savings target and associated restructuring costs, plus resolution of FDA and product-liability matters.